Total: £ 56.28
Published Date: 2026-03-24 | Pages: 147 | Tables: 140 | Pharma & Healthcare
The global Brain and Central Nervous System Cancer Treatments market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Brain and Central Nervous System Cancer Treatments competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Tumors in the brain and spinal cord are called central nervous system (CNS) tumors. These tumors occur when abnormal cells form in any part of the brain or spine area. A tumor may be benign, meaning it does not have cancer cells, or malignant, meaning cancer is present.
The North American market for Brain and Central Nervous System Cancer Treatments is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Brain and Central Nervous System Cancer Treatments is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Brain and Central Nervous System Cancer Treatments include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Brain and Central Nervous System Cancer Treatments market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Brain and Central Nervous System Cancer Treatments. The Brain and Central Nervous System Cancer Treatments market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Brain and Central Nervous System Cancer Treatments market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Brain and Central Nervous System Cancer Treatments manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
by Application
Brain Cancer
Spinal Cord Cancer
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Brain and Central Nervous System Cancer Treatments manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Brain and Central Nervous System Cancer Treatments sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Brain and Central Nervous System Cancer Treatments Market Overview
1.1 Product Definition
1.2 Brain and Central Nervous System Cancer Treatments by Type
1.2.1 Global Brain and Central Nervous System Cancer Treatments Market Value by Type: 2025 vs 2032
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
1.3 Brain and Central Nervous System Cancer Treatments by Application
1.3.1 Global Brain and Central Nervous System Cancer Treatments Market Value by Application: 2025 vs 2032
1.3.2 Brain Cancer
1.3.3 Spinal Cord Cancer
1.3.4 Others
1.4 Global Brain and Central Nervous System Cancer Treatments Market Size Estimates and Forecasts
1.4.1 Global Brain and Central Nervous System Cancer Treatments Revenue 2021–2032
1.4.2 Global Brain and Central Nervous System Cancer Treatments Sales 2021–2032
1.4.3 Global Brain and Central Nervous System Cancer Treatments Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Brain and Central Nervous System Cancer Treatments Market Competition by Manufacturers
2.1 Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Manufacturers (2021–2026)
2.2 Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Brain and Central Nervous System Cancer Treatments Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Brain and Central Nervous System Cancer Treatments, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Brain and Central Nervous System Cancer Treatments, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Brain and Central Nervous System Cancer Treatments, Product Types and Applications
2.7 Global Key Manufacturers of Brain and Central Nervous System Cancer Treatments, Date of Entry into the Industry
2.8 Global Brain and Central Nervous System Cancer Treatments Market Competitive Situation and Trends
2.8.1 Global Brain and Central Nervous System Cancer Treatments Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Brain and Central Nervous System Cancer Treatments Players Market Share by Revenue
2.8.3 Global Brain and Central Nervous System Cancer Treatments Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Brain and Central Nervous System Cancer Treatments Market Scenario by Region
3.1 Global Brain and Central Nervous System Cancer Treatments Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Brain and Central Nervous System Cancer Treatments Sales by Region: 2021–2032
3.2.1 Global Brain and Central Nervous System Cancer Treatments Sales by Region: 2021–2026
3.2.2 Global Brain and Central Nervous System Cancer Treatments Sales by Region: 2027–2032
3.3 Global Brain and Central Nervous System Cancer Treatments Revenue by Region: 2021–2032
3.3.1 Global Brain and Central Nervous System Cancer Treatments Revenue by Region: 2021–2026
3.3.2 Global Brain and Central Nervous System Cancer Treatments Revenue by Region: 2027–2032
3.4 North America Brain and Central Nervous System Cancer Treatments Market Facts & Figures by Country
3.4.1 North America Brain and Central Nervous System Cancer Treatments Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Brain and Central Nervous System Cancer Treatments Sales by Country (2021–2032)
3.4.3 North America Brain and Central Nervous System Cancer Treatments Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Brain and Central Nervous System Cancer Treatments Market Facts & Figures by Country
3.5.1 Europe Brain and Central Nervous System Cancer Treatments Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Brain and Central Nervous System Cancer Treatments Sales by Country (2021–2032)
3.5.3 Europe Brain and Central Nervous System Cancer Treatments Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Brain and Central Nervous System Cancer Treatments Market Facts & Figures by Region
3.6.1 Asia Pacific Brain and Central Nervous System Cancer Treatments Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Brain and Central Nervous System Cancer Treatments Sales by Region (2021–2032)
3.6.3 Asia Pacific Brain and Central Nervous System Cancer Treatments Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Brain and Central Nervous System Cancer Treatments Market Facts & Figures by Country
3.7.1 Latin America Brain and Central Nervous System Cancer Treatments Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Brain and Central Nervous System Cancer Treatments Sales by Country (2021–2032)
3.7.3 Latin America Brain and Central Nervous System Cancer Treatments Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Brain and Central Nervous System Cancer Treatments Market Facts & Figures by Country
3.8.1 Middle East and Africa Brain and Central Nervous System Cancer Treatments Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales by Country (2021–2032)
3.8.3 Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Brain and Central Nervous System Cancer Treatments Sales by Type (2021–2032)
4.1.1 Global Brain and Central Nervous System Cancer Treatments Sales by Type (2021–2026)
4.1.2 Global Brain and Central Nervous System Cancer Treatments Sales by Type (2027–2032)
4.1.3 Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Type (2021–2032)
4.2 Global Brain and Central Nervous System Cancer Treatments Revenue by Type (2021–2032)
4.2.1 Global Brain and Central Nervous System Cancer Treatments Revenue by Type (2021–2026)
4.2.2 Global Brain and Central Nervous System Cancer Treatments Revenue by Type (2027–2032)
4.2.3 Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Type (2021–2032)
4.3 Global Brain and Central Nervous System Cancer Treatments Price by Type (2021–2032)
5 Segment by Application
5.1 Global Brain and Central Nervous System Cancer Treatments Sales by Application (2021–2032)
5.1.1 Global Brain and Central Nervous System Cancer Treatments Sales by Application (2021–2026)
5.1.2 Global Brain and Central Nervous System Cancer Treatments Sales by Application (2027–2032)
5.1.3 Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Application (2021–2032)
5.2 Global Brain and Central Nervous System Cancer Treatments Revenue by Application (2021–2032)
5.2.1 Global Brain and Central Nervous System Cancer Treatments Revenue by Application (2021–2026)
5.2.2 Global Brain and Central Nervous System Cancer Treatments Revenue by Application (2027–2032)
5.2.3 Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Application (2021–2032)
5.3 Global Brain and Central Nervous System Cancer Treatments Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Brain and Central Nervous System Cancer Treatments Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Celgene
6.2.1 Celgene Company Information
6.2.2 Celgene Description and Business Overview
6.2.3 Celgene Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Celgene Brain and Central Nervous System Cancer Treatments Product Portfolio
6.2.5 Celgene Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Company Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Novartis Brain and Central Nervous System Cancer Treatments Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Company Information
6.4.2 Bristol-Myers Squibb Description and Business Overview
6.4.3 Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Company Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Johnson & Johnson Brain and Central Nervous System Cancer Treatments Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Merck & Co.
6.6.1 Merck & Co. Company Information
6.6.2 Merck & Co. Description and Business Overview
6.6.3 Merck & Co. Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Merck & Co. Brain and Central Nervous System Cancer Treatments Product Portfolio
6.6.5 Merck & Co. Recent Developments/Updates
6.7 AstraZeneca
6.7.1 AstraZeneca Company Information
6.7.2 AstraZeneca Description and Business Overview
6.7.3 AstraZeneca Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 AstraZeneca Brain and Central Nervous System Cancer Treatments Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Company Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Pfizer Brain and Central Nervous System Cancer Treatments Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Amgen
6.9.1 Amgen Company Information
6.9.2 Amgen Description and Business Overview
6.9.3 Amgen Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Amgen Brain and Central Nervous System Cancer Treatments Product Portfolio
6.9.5 Amgen Recent Developments/Updates
6.10 Eli Lilly
6.10.1 Eli Lilly Company Information
6.10.2 Eli Lilly Description and Business Overview
6.10.3 Eli Lilly Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Eli Lilly Brain and Central Nervous System Cancer Treatments Product Portfolio
6.10.5 Eli Lilly Recent Developments/Updates
6.11 AbbVie
6.11.1 AbbVie Company Information
6.11.2 AbbVie Description and Business Overview
6.11.3 AbbVie Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 AbbVie Brain and Central Nervous System Cancer Treatments Product Portfolio
6.11.5 AbbVie Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Company Information
6.12.2 Takeda Description and Business Overview
6.12.3 Takeda Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Takeda Brain and Central Nervous System Cancer Treatments Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 Astellas
6.13.1 Astellas Company Information
6.13.2 Astellas Description and Business Overview
6.13.3 Astellas Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Astellas Brain and Central Nervous System Cancer Treatments Product Portfolio
6.13.5 Astellas Recent Developments/Updates
6.14 Ipsen
6.14.1 Ipsen Company Information
6.14.2 Ipsen Description and Business Overview
6.14.3 Ipsen Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Ipsen Brain and Central Nervous System Cancer Treatments Product Portfolio
6.14.5 Ipsen Recent Developments/Updates
6.15 Sanofi
6.15.1 Sanofi Company Information
6.15.2 Sanofi Description and Business Overview
6.15.3 Sanofi Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Sanofi Brain and Central Nervous System Cancer Treatments Product Portfolio
6.15.5 Sanofi Recent Developments/Updates
6.16 Bayer
6.16.1 Bayer Company Information
6.16.2 Bayer Description and Business Overview
6.16.3 Bayer Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Bayer Brain and Central Nervous System Cancer Treatments Product Portfolio
6.16.5 Bayer Recent Developments/Updates
6.17 Biogen Idec
6.17.1 Biogen Idec Company Information
6.17.2 Biogen Idec Description and Business Overview
6.17.3 Biogen Idec Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Biogen Idec Brain and Central Nervous System Cancer Treatments Product Portfolio
6.17.5 Biogen Idec Recent Developments/Updates
6.18 Teva
6.18.1 Teva Company Information
6.18.2 Teva Description and Business Overview
6.18.3 Teva Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Teva Brain and Central Nervous System Cancer Treatments Product Portfolio
6.18.5 Teva Recent Developments/Updates
6.19 Otsuka
6.19.1 Otsuka Company Information
6.19.2 Otsuka Description and Business Overview
6.19.3 Otsuka Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Otsuka Brain and Central Nervous System Cancer Treatments Product Portfolio
6.19.5 Otsuka Recent Developments/Updates
6.20 Eisai
6.20.1 Eisai Company Information
6.20.2 Eisai Description and Business Overview
6.20.3 Eisai Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 Eisai Brain and Central Nervous System Cancer Treatments Product Portfolio
6.20.5 Eisai Recent Developments/Updates
6.21 Merck KGaA
6.21.1 Merck KGaA Company Information
6.21.2 Merck KGaA Description and Business Overview
6.21.3 Merck KGaA Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.21.4 Merck KGaA Brain and Central Nervous System Cancer Treatments Product Portfolio
6.21.5 Merck KGaA Recent Developments/Updates
6.22 Gilead Sciences
6.22.1 Gilead Sciences Company Information
6.22.2 Gilead Sciences Description and Business Overview
6.22.3 Gilead Sciences Brain and Central Nervous System Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.22.4 Gilead Sciences Brain and Central Nervous System Cancer Treatments Product Portfolio
6.22.5 Gilead Sciences Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Brain and Central Nervous System Cancer Treatments Industry Chain Analysis
7.2 Brain and Central Nervous System Cancer Treatments Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Brain and Central Nervous System Cancer Treatments Production Mode & Process Analysis
7.4 Brain and Central Nervous System Cancer Treatments Sales and Marketing
7.4.1 Brain and Central Nervous System Cancer Treatments Sales Channels
7.4.2 Brain and Central Nervous System Cancer Treatments Distributors
7.5 Brain and Central Nervous System Cancer Treatments Customer Analysis
8 Brain and Central Nervous System Cancer Treatments Market Dynamics
8.1 Brain and Central Nervous System Cancer Treatments Industry Trends
8.2 Brain and Central Nervous System Cancer Treatments Market Drivers
8.3 Brain and Central Nervous System Cancer Treatments Market Challenges
8.4 Brain and Central Nervous System Cancer Treatments Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Brain and Central Nervous System Cancer Treatments Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Brain and Central Nervous System Cancer Treatments Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Brain and Central Nervous System Cancer Treatments Market Competitive Situation by Manufacturers in 2025
Table 4. Global Brain and Central Nervous System Cancer Treatments Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Brain and Central Nervous System Cancer Treatments Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Brain and Central Nervous System Cancer Treatments Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Brain and Central Nervous System Cancer Treatments Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Brain and Central Nervous System Cancer Treatments, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Brain and Central Nervous System Cancer Treatments, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Brain and Central Nervous System Cancer Treatments, Product Types and Applications
Table 12. Global Key Manufacturers of Brain and Central Nervous System Cancer Treatments, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Brain and Central Nervous System Cancer Treatments Companies by Tier (Tier 1, Tier 2, Tier 3), based on Brain and Central Nervous System Cancer Treatments Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Brain and Central Nervous System Cancer Treatments Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Brain and Central Nervous System Cancer Treatments Sales by Region (K Units), 2021–2026
Table 18. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Region (2021–2026)
Table 19. Global Brain and Central Nervous System Cancer Treatments Sales by Region (K Units), 2027–2032
Table 20. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Region (2027–2032)
Table 21. Global Brain and Central Nervous System Cancer Treatments Revenue by Region (US$ Million), 2021–2026
Table 22. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Region (2021–2026)
Table 23. Global Brain and Central Nervous System Cancer Treatments Revenue by Region (US$ Million), 2027–2032
Table 24. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Region (2027–2032)
Table 25. North America Brain and Central Nervous System Cancer Treatments Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Brain and Central Nervous System Cancer Treatments Sales by Country (K Units), 2021–2026
Table 27. North America Brain and Central Nervous System Cancer Treatments Sales by Country (K Units), 2027–2032
Table 28. North America Brain and Central Nervous System Cancer Treatments Revenue by Country (US$ Million), 2021–2026
Table 29. North America Brain and Central Nervous System Cancer Treatments Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Brain and Central Nervous System Cancer Treatments Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Brain and Central Nervous System Cancer Treatments Sales by Country (K Units), 2021–2026
Table 32. Europe Brain and Central Nervous System Cancer Treatments Sales by Country (K Units), 2027–2032
Table 33. Europe Brain and Central Nervous System Cancer Treatments Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Brain and Central Nervous System Cancer Treatments Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Brain and Central Nervous System Cancer Treatments Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Brain and Central Nervous System Cancer Treatments Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Brain and Central Nervous System Cancer Treatments Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Brain and Central Nervous System Cancer Treatments Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Brain and Central Nervous System Cancer Treatments Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Brain and Central Nervous System Cancer Treatments Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Brain and Central Nervous System Cancer Treatments Sales by Country (K Units), 2021–2026
Table 42. Latin America Brain and Central Nervous System Cancer Treatments Sales by Country (K Units), 2027–2032
Table 43. Latin America Brain and Central Nervous System Cancer Treatments Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Brain and Central Nervous System Cancer Treatments Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue by Country (US$ Million), 2027–2032
Table 50. Global Brain and Central Nervous System Cancer Treatments Sales (K Units) by Type (2021–2026)
Table 51. Global Brain and Central Nervous System Cancer Treatments Sales (K Units) by Type (2027–2032)
Table 52. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Type (2021–2026)
Table 53. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Type (2027–2032)
Table 54. Global Brain and Central Nervous System Cancer Treatments Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Brain and Central Nervous System Cancer Treatments Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Type (2021–2026)
Table 57. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Type (2027–2032)
Table 58. Global Brain and Central Nervous System Cancer Treatments Price (US$/Unit) by Type (2021–2026)
Table 59. Global Brain and Central Nervous System Cancer Treatments Price (US$/Unit) by Type (2027–2032)
Table 60. Global Brain and Central Nervous System Cancer Treatments Sales (K Units) by Application (2021–2026)
Table 61. Global Brain and Central Nervous System Cancer Treatments Sales (K Units) by Application (2027–2032)
Table 62. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Application (2021–2026)
Table 63. Global Brain and Central Nervous System Cancer Treatments Sales Market Share by Application (2027–2032)
Table 64. Global Brain and Central Nervous System Cancer Treatments Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Brain and Central Nervous System Cancer Treatments Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Application (2021–2026)
Table 67. Global Brain and Central Nervous System Cancer Treatments Revenue Market Share by Application (2027–2032)
Table 68. Global Brain and Central Nervous System Cancer Treatments Price (US$/Unit) by Application (2021–2026)
Table 69. Global Brain and Central Nervous System Cancer Treatments Price (US$/Unit) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche Brain and Central Nervous System Cancer Treatments Product
Table 74. Roche Recent Developments/Updates
Table 75. Celgene Company Information
Table 76. Celgene Description and Business Overview
Table 77. Celgene Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Celgene Brain and Central Nervous System Cancer Treatments Product
Table 79. Celgene Recent Developments/Updates
Table 80. Novartis Company Information
Table 81. Novartis Description and Business Overview
Table 82. Novartis Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Novartis Brain and Central Nervous System Cancer Treatments Product
Table 84. Novartis Recent Developments/Updates
Table 85. Bristol-Myers Squibb Company Information
Table 86. Bristol-Myers Squibb Description and Business Overview
Table 87. Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Bristol-Myers Squibb Brain and Central Nervous System Cancer Treatments Product
Table 89. Bristol-Myers Squibb Recent Developments/Updates
Table 90. Johnson & Johnson Company Information
Table 91. Johnson & Johnson Description and Business Overview
Table 92. Johnson & Johnson Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Johnson & Johnson Brain and Central Nervous System Cancer Treatments Product
Table 94. Johnson & Johnson Recent Developments/Updates
Table 95. Merck & Co. Company Information
Table 96. Merck & Co. Description and Business Overview
Table 97. Merck & Co. Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Merck & Co. Brain and Central Nervous System Cancer Treatments Product
Table 99. Merck & Co. Recent Developments/Updates
Table 100. AstraZeneca Company Information
Table 101. AstraZeneca Description and Business Overview
Table 102. AstraZeneca Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. AstraZeneca Brain and Central Nervous System Cancer Treatments Product
Table 104. AstraZeneca Recent Developments/Updates
Table 105. Pfizer Company Information
Table 106. Pfizer Description and Business Overview
Table 107. Pfizer Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Pfizer Brain and Central Nervous System Cancer Treatments Product
Table 109. Pfizer Recent Developments/Updates
Table 110. Amgen Company Information
Table 111. Amgen Description and Business Overview
Table 112. Amgen Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Amgen Brain and Central Nervous System Cancer Treatments Product
Table 114. Amgen Recent Developments/Updates
Table 115. Eli Lilly Company Information
Table 116. Eli Lilly Description and Business Overview
Table 117. Eli Lilly Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Eli Lilly Brain and Central Nervous System Cancer Treatments Product
Table 119. Eli Lilly Recent Developments/Updates
Table 120. AbbVie Company Information
Table 121. AbbVie Description and Business Overview
Table 122. AbbVie Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. AbbVie Brain and Central Nervous System Cancer Treatments Product
Table 124. AbbVie Recent Developments/Updates
Table 125. Takeda Company Information
Table 126. Takeda Description and Business Overview
Table 127. Takeda Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Takeda Brain and Central Nervous System Cancer Treatments Product
Table 129. Takeda Recent Developments/Updates
Table 130. Astellas Company Information
Table 131. Astellas Description and Business Overview
Table 132. Astellas Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Astellas Brain and Central Nervous System Cancer Treatments Product
Table 134. Astellas Recent Developments/Updates
Table 135. Ipsen Company Information
Table 136. Ipsen Description and Business Overview
Table 137. Ipsen Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Ipsen Brain and Central Nervous System Cancer Treatments Product
Table 139. Ipsen Recent Developments/Updates
Table 140. Sanofi Company Information
Table 141. Sanofi Description and Business Overview
Table 142. Sanofi Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Sanofi Brain and Central Nervous System Cancer Treatments Product
Table 144. Sanofi Recent Developments/Updates
Table 145. Bayer Company Information
Table 146. Bayer Description and Business Overview
Table 147. Bayer Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. Bayer Brain and Central Nervous System Cancer Treatments Product
Table 149. Bayer Recent Developments/Updates
Table 150. Biogen Idec Company Information
Table 151. Biogen Idec Description and Business Overview
Table 152. Biogen Idec Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 153. Biogen Idec Brain and Central Nervous System Cancer Treatments Product
Table 154. Biogen Idec Recent Developments/Updates
Table 155. Teva Company Information
Table 156. Teva Description and Business Overview
Table 157. Teva Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 158. Teva Brain and Central Nervous System Cancer Treatments Product
Table 159. Teva Recent Developments/Updates
Table 160. Otsuka Company Information
Table 161. Otsuka Description and Business Overview
Table 162. Otsuka Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 163. Otsuka Brain and Central Nervous System Cancer Treatments Product
Table 164. Otsuka Recent Developments/Updates
Table 165. Eisai Company Information
Table 166. Eisai Description and Business Overview
Table 167. Eisai Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 168. Eisai Brain and Central Nervous System Cancer Treatments Product
Table 169. Eisai Recent Developments/Updates
Table 170. Merck KGaA Company Information
Table 171. Merck KGaA Description and Business Overview
Table 172. Merck KGaA Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 173. Merck KGaA Brain and Central Nervous System Cancer Treatments Product
Table 174. Merck KGaA Recent Developments/Updates
Table 175. Gilead Sciences Company Information
Table 176. Gilead Sciences Description and Business Overview
Table 177. Gilead Sciences Brain and Central Nervous System Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 178. Gilead Sciences Brain and Central Nervous System Cancer Treatments Product
Table 179. Gilead Sciences Recent Developments/Updates
Table 180. Key Raw Materials Lists
Table 181. Raw Materials Key Suppliers Lists
Table 182. Brain and Central Nervous System Cancer Treatments Distributors List
Table 183. Brain and Central Nervous System Cancer Treatments Customers List
Table 184. Brain and Central Nervous System Cancer Treatments Market Trends
Table 185. Brain and Central Nervous System Cancer Treatments Market Drivers
Table 186. Brain and Central Nervous System Cancer Treatments Market Challenges
Table 187. Brain and Central Nervous System Cancer Treatments Market Restraints
Table 188. Research Programs/Design for This Report
Table 189. Key Data Information from Secondary Sources
Table 190. Key Data Information from Primary Sources
Table 191. Authors List of This Report
List of Figures
Figure 1. Product Picture of Brain and Central Nervous System Cancer Treatments
Figure 2. Global Brain and Central Nervous System Cancer Treatments Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Brain and Central Nervous System Cancer Treatments Market Share by Type: 2025 & 2032
Figure 4. Chemotherapy Product Picture
Figure 5. Targeted Therapy Product Picture
Figure 6. Immunotherapy (Biologic Therapy) Product Picture
Figure 7. Hormonal Therapy Product Picture
Figure 8. Others Product Picture
Figure 9. Global Brain and Central Nervous System Cancer Treatments Market Value by Application (US$ Million), 2021–2032
Figure 10. Global Brain and Central Nervous System Cancer Treatments Market Share by Application: 2025 & 2032
Figure 11. Brain Cancer
Figure 12. Spinal Cord Cancer
Figure 13. Others
Figure 14. Global Brain and Central Nervous System Cancer Treatments Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Brain and Central Nervous System Cancer Treatments Market Size (US$ Million), 2021–2032
Figure 16. Global Brain and Central Nervous System Cancer Treatments Sales (K Units), 2021–2032
Figure 17. Global Brain and Central Nervous System Cancer Treatments Average Price (US$/Unit), 2021–2032
Figure 18. Brain and Central Nervous System Cancer Treatments Report Years Considered
Figure 19. Brain and Central Nervous System Cancer Treatments Sales Share by Manufacturers in 2025
Figure 20. Global Brain and Central Nervous System Cancer Treatments Revenue Share by Manufacturers in 2025
Figure 21. Top 5 and Top 10 Global Brain and Central Nervous System Cancer Treatments Players: Market Share by Revenue in Brain and Central Nervous System Cancer Treatments in 2025
Figure 22. Brain and Central Nervous System Cancer Treatments Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 23. Global Brain and Central Nervous System Cancer Treatments Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 24. North America Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021–2032)
Figure 25. North America Brain and Central Nervous System Cancer Treatments Revenue Market Share by Country (2021–2032)
Figure 26. United States Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Canada Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Europe Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021–2032)
Figure 29. Europe Brain and Central Nervous System Cancer Treatments Revenue Market Share by Country (2021–2032)
Figure 30. Germany Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. France Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. U.K. Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Italy Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Russia Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Asia Pacific Brain and Central Nervous System Cancer Treatments Sales Market Share by Region (2021–2032)
Figure 36. Asia Pacific Brain and Central Nervous System Cancer Treatments Revenue Market Share by Region (2021–2032)
Figure 37. China Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Japan Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. South Korea Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. India Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Australia Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. China Taiwan Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Southeast Asia Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Latin America Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021–2032)
Figure 45. Latin America Brain and Central Nervous System Cancer Treatments Revenue Market Share by Country (2021–2032)
Figure 46. Mexico Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Brazil Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Argentina Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Colombia Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Middle East and Africa Brain and Central Nervous System Cancer Treatments Sales Market Share by Country (2021–2032)
Figure 51. Middle East and Africa Brain and Central Nervous System Cancer Treatments Revenue Market Share by Country (2021–2032)
Figure 52. Turkey Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Saudi Arabia Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. UAE Brain and Central Nervous System Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Global Sales Market Share of Brain and Central Nervous System Cancer Treatments by Type (2021–2032)
Figure 56. Global Revenue Market Share of Brain and Central Nervous System Cancer Treatments by Type (2021–2032)
Figure 57. Global Brain and Central Nervous System Cancer Treatments Price (US$/Unit) by Type (2021–2032)
Figure 58. Global Sales Market Share of Brain and Central Nervous System Cancer Treatments by Application (2021–2032)
Figure 59. Global Revenue Market Share of Brain and Central Nervous System Cancer Treatments by Application (2021–2032)
Figure 60. Global Brain and Central Nervous System Cancer Treatments Price (US$/Unit) by Application (2021–2032)
Figure 61. Brain and Central Nervous System Cancer Treatments Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed